About Us

Partnerships

Creating value through collaboration and expanding our opportunities to improve patient care and outcomes.
Our Pipeline Targets Large Cancer Indications
Read More >

Partnerships

Cascadian Therapeutics Corporate Development Strategy

We may enter into collaborations, acquisitions or license arrangements to advance the development or potential commercialization of programs in our pipeline, including partnering, consistent with our mission of developing novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients.

Array BioPharma

Cascadian Therapeutics has obtained an exclusive license from Array BioPharma for the manufacture, development and commercialization of tucatinib, and we are currently developing tucatinib for the treatment of HER2+ metastatic breast cancer.

Sentinel Oncology

Cascadian Therapeutics is collaborating with Sentinel Oncology Ltd., Cambridge, UK, for the discovery of novel small molecule inhibitors of checkpoint kinase 1.

Adimab LLC

Cascadian Therapeutics is collaborating with Adimab LLC, Lebanon, NH, for the discovery of novel antibodies against undisclosed immunotherapy targets in oncology.

Our Pipeline Targets Large Cancer Indications
Read More >